News und Analysen
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Equity markets can be highly volatile in the short run. Where the S&P 500 might land in the next six months is anyone's guess. However, over a decade, major indexes tend to move steadily in the
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its
2 Growth Stocks to Buy at a Discount
The stock market is on fire as 2024 kicks off. As a result, many investors might be reviewing their long-term financial goals as well as their plans for stock purchases. As always, it's best to
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's
2 Bargain Basement Stocks to Buy Now and Hold Forever
Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around
Is Vertex Pharmaceuticals Stock a Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are
3 Stocks That Could Trounce the Market in 2024
Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.
Three Motley Fool contributors think
Could Vertex Pharmaceuticals Reach $500 in 2024?
Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
Centene (CNC) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Centene (NYSE: CNC)Q4 2023 Earnings CallFeb 06, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2023 Earnings CallFeb 05, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why AbbVie Stock Flew Higher on Monday
Still basking in the afterglow of an encouraging quarterly earnings report, AbbVie (NYSE: ABBV) stock saw a healthy 1.5% rise in price across Monday's trading session. What helped was a series of
2 Stocks to Buy Near Their 52-Week Highs
When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be